Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

European Journal of Clinical Pharmacology
Kazushi SawamuraToshiyuki Someya

Abstract

We investigated the effect of dosages of paroxetine and cytochrome P450 (CYP) 2D6 genotypes on the plasma concentration of paroxetine in Japanese patients being treated with paroxetine. Blood samples were collected from 73 individuals after at least 2 weeks of the same daily dose of paroxetine. The plasma paroxetine concentration was measured using HPLC, and the CYP2D6 genotypes were identified by PCR. Genotype groups were compared by one-way analysis of variance at different paroxetine doses. The mean plasma paroxetine concentrations at daily doses of 10, 20, 30, and 40 ng/ml were 6.6+/-7.4, 34.9+/-26.8, 74.8+/-37.2, and 130.5+/-96.8 ng/ml, respectively, showing a disproportionate and nonlinear increase in plasma drug levels of paroxetine upon increasing doses. Plasma paroxetine concentrations in patients with CYP2D6*10 alleles were significantly higher than those without *10 allele at 10 mg/day (7.3+/-6.11 vs. 2.99+/-3.52 ng/ml), but there was no significant difference between *1/ *1, *1/ *10 and *10/ *10 genotypes at the higher doses. Similarly, patients with CYP2D6*5 alleles showed higher plasma paroxetine concentrations than those without *5 allele, although differences in the plasma paroxetine concentration did not reach ...Continue Reading

References

Mar 1, 1992·Clinical Pharmacology and Therapeutics·S H SindrupT C Tasker
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·C M KayeW H Greb
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·I JohanssonM Ingelman-Sundberg
Jan 1, 1997·Acta Psychiatrica Scandinavica. Supplementum·L BertilssonG Tybring
May 26, 1999·Clinical Pharmacology and Therapeutics·T TateishiS Kobayashi
Aug 13, 2002·Journal of Clinical Psychopharmacology·Kazutaka ShimodaMasako Okawa
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Toshiyuki SomeyaSaburo Takahashi

❮ Previous
Next ❯

Citations

Sep 9, 2006·European Journal of Clinical Pharmacology·GuoXiang WangXiangMing Fang
Nov 25, 2006·European Journal of Clinical Pharmacology·Norio Yasui-FurukoriSunao Kaneko
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert L FindlingTheodore M Danoff
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mugdha ThakurDavid B Matchar
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·UNKNOWN Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Yolande Lucire, Christopher Crotty
Oct 22, 2009·Pharmacogenomics·Ibrahim A Abdel-Hamid, Karl-Erik Andersson
Apr 28, 2011·Pharmacogenomics·Bob WilffertLolkje T W de Jong-van den Berg
Sep 26, 2006·Fukushima Journal of Medical Science·Koichiro SatohToshio Kobayashi
Oct 25, 2013·International Review of Psychiatry·C Anthony AltarDavid Mrazek
Jan 5, 2011·Expert Opinion on Drug Metabolism & Toxicology·Nikolaos KokrasZeta Papadopoulou-Daifoti
Jul 9, 2011·Expert Opinion on Drug Metabolism & Toxicology·Stefano PorcelliDiana De Ronchi
Jun 2, 2015·Expert Opinion on Drug Metabolism & Toxicology·Kristina Probst-SchendzielorzJulia C Stingl
May 4, 2006·British Journal of Clinical Pharmacology·Yan FengRobert R Bies
Jul 16, 2013·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Chiara FabbriAlessandro Serretti
Jan 21, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mikito UedaKazutaka Shimoda
May 15, 2015·Clinical Pharmacology and Therapeutics·J K HicksUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Oct 29, 2013·Pharmacology, Biochemistry, and Behavior·Olivia F O'LearyJohn F Cryan
May 20, 2015·Current Psychiatry Reports·Chiara Fabbri, Alessandro Serretti
Sep 10, 2014·Journal of Neural Transmission·Edoardo Spina, Jose de Leon
Aug 17, 2016·International Journal of Molecular Sciences·Aizati N A DaudBob Wilffert
Jul 31, 2016·Journal of Attention Disorders·Atsunori SugimotoToshiyuki Someya
Apr 28, 2018·Expert Review of Molecular Diagnostics·Cristina MoraAnnamaria Cattaneo
Apr 25, 2006·Journal of Clinical Psychopharmacology·Cüneyt Güzey, Olav Spigset
Nov 4, 2008·Therapeutic Drug Monitoring·Junzo WatanabeToshiyuki Someya
Feb 17, 2007·Therapeutic Drug Monitoring·Takashi WatanabeKazutaka Shimoda
Jan 1, 2012·ISRN Bioinformatics·John A SpringerMichael D Kane
Jul 13, 2019·Current Opinion in Pharmacology·Yasmin SchmidSimon M Mueller
Jul 22, 2008·Therapeutic Drug Monitoring·Marianne Gex-FabryGilles Bertschy
May 13, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·C B EapC Hiemke
May 19, 2021·Pharmacology Research & Perspectives·Shanna C TrenamanKerry Goralski

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.